FATE Shares Outstanding History



Below is a table of the FATE shares outstanding history going back to 9/18/2013:

Date FATE Shares Outstanding
9/18/201314.69M
11/11/201320.36M
3/13/201420.44M
5/9/201420.51M
8/7/201420.56M
11/11/201420.57M
3/12/201520.64M
5/5/201520.68M
8/3/201528.69M
11/2/201528.72M
3/2/201628.86M
5/6/201628.86M
8/5/201628.89M
11/4/201634.15M
3/13/201741.39M
5/12/201741.40M
8/14/201741.42M
10/31/201741.69M
3/2/201852.77M
5/7/201852.86M
8/3/201853.42M
10/30/201864.52M
3/1/201965.00M
5/6/201965.19M
8/5/201965.39M
11/4/201975.59M
2/28/202075.93M
5/7/202077.69M
8/3/202086.84M
11/3/202087.24M
2/22/202193.78M
5/3/202194.04M
8/2/202195.18M
10/28/202195.49M
2/24/202296.43M
4/28/202296.63M
7/28/202297.00M
10/27/202297.17M
2/22/202398.16M
4/27/202398.38M
8/2/202398.56M
10/31/202398.60M

Also see: FATE Market Cap History
FATE YTD Return
FATE Historical Shares Outstanding:
+20.69% CAGR
FATE Historical Shares Outstanding: +20.69% CAGR

Mouse over chart for data details
9/18/2013 ...10/31/2023
Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC) derived cellular immunotherapy pipeline include: FT516, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a high-affinity, non-cleavable CD16 Fc receptor; and FT596, which is an off-the-shelf chimeric antigen receptor NK cell cancer immunotherapy derived from a clonal engineered master iPSC line. We show 42 historical shares outstanding datapoints in our coverage of FATE's shares outstanding history.

Understanding the changing numbers of FATE shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like FATE versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching FATE by allowing them to research FATE shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree FATE Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Fate Therapeutics (FATE) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

FBIO Shares Outstanding History
FBRX Shares Outstanding History
FCRE Shares Outstanding History
FCSC Shares Outstanding History
FDMT Shares Outstanding History
FEMY Shares Outstanding History
FGEN Shares Outstanding History
FHTX Shares Outstanding History
FIXX Shares Outstanding History
FLDM Shares Outstanding History
More Healthcare companies »

 

FATE Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.